{"url_path":"/sec/nvct/8-k/2026-06-12/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1875558/0001104659-26-073419-index.html","accession_number":"0001104659-26-073419","cik":"0001875558","ticker":"NVCT","issuer_name":"Nuvectis Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1875558/0001104659-26-073419-index.html","primary_entity_key":"0001875558","primary_entity_name":"Nuvectis Pharma, Inc."},"word_count":360,"has_tables":true,"body_markdown":"**Item 5.07.**\n**Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn Thursday, June 11, 2026,\nat 10:00 a.m. Eastern Time, by means of an online meeting platform, Nuvectis Pharma, Inc. (the “Company”) held its 2026 Annual\nMeeting (the “Annual Meeting”).\n\n \n\nThe Company's Definitive\nProxy Statement on Schedule 14A (the “Proxy”), filed with the U.S. Securities and Exchange Commission (the “SEC”)\non April 27, 2026, inadvertently misstated the total number of shares of common stock outstanding as of the record date of April 13,\n2026, as 27,668,036. The correct number of shares of common stock outstanding as of the record date was 26,614,628. This correction does\nnot affect the validity of any votes cast at the Annual Meeting or the outcome of any proposal voted upon.\n\n \n\nStockholders\nrepresenting 16,193,686, or 60.8%, of the 26,614,628 shares of common stock outstanding on the record date of April 13, 2026, were\npresent in person or by proxy, constituting a quorum under applicable law. Proxies were solicited by the Company pursuant to Regulation\n14A under the Securities Exchange Act of 1934, as amended. Each of the proposals below is described in detail in the Company’s Proxy\nfor the Annual Meeting, filed with the SEC on April 27, 2026. At the Annual Meeting, all of the proposals were approved.\n\n \n\nThe results are as follows:\n\n \n\n**Proposal 1**\n\n \n\nThe vote with respect to the election of the Class\nI director to hold office until the 2029 annual meeting was as follows:\n\n \n\nDirector \nVotes For \nVotes\nAgainst \nAbstentions / Votes Withheld \nBroker Non-Votes\n\nRon Bentsur \n8,354,838 \n391,265 \n216 \n7,447,367\n\n \n\n**Proposal 2**\n\n \n\nThe vote with respect to the ratification of Kesselman\n& Kesselman as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was\nas follows:\n\n \n\nVotes For \nVotes Against \nAbstentions / Votes Withheld \nBroker Non-Votes\n\n15,662,222 \n10,574 \n520,890 \n-\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized.\n\n \n\n \n**Nuvectis Pharma, Inc.**\n\n \n(Registrant)\n\n \n \n \n\nDate: June 12, 2026\n \n \n\n \nBy:\n/s/ Ron Bentsur\n\n \n \nRon Bentsur\n\n \n \nChairman, Chief Executive Officer and President"}